Guanidine Hydrazone (2a): A Novel Disease-Modifying Treatment for Parkinson's Disease

被引：0
|
作者：
Persico, Michele [1 ]
Fang, Tracy Shi Zhang [1 ]
Eleuteri, Simona Carmen [1 ]
Simon, David Keith [1 ]
机构：
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
来源：
ANNALS OF NEUROLOGY | 2023年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S221
引用
收藏
页码：S174 / S174
页数：1
相关论文
共 50 条
  • [41] TREATMENT - DISEASE-MODIFYING THERAPIES
    LIEBERMAN, JD
    SCHATTEN, S
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1988, 14 (01) : 223 - 243
  • [42] Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial
    Cicchetti, F.
    David, L. S.
    Siddu, A.
    Denis, H. L.
    NEUROBIOLOGY OF DISEASE, 2019, 130
  • [43] Norvaline, a novel Alzheimer's disease-modifying agent
    Polis, B.
    Samson, A.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 133 - 133
  • [44] Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease A Randomized Clinical Trial
    Stevens, Kara N.
    Creanor, Siobhan
    Jeffery, Alison
    Whone, Alan
    Zajicek, John
    Foggo, Andy
    Jones, Ben
    Chapman, Rebecca
    Cocking, Laura
    Wilks, Jonny
    Webb, Doug
    Carroll, Camille
    JAMA NEUROLOGY, 2022, 79 (12) : 1232 - 1241
  • [45] ROCK Inhibition by Fasudil as Disease-Modifying Translational Approach in the Treatment of Parkinson's Disease and Amyotrophic Lateral Sclerosis
    Lingor, Paul
    Tatenhorst, Lars
    Koch, Jan
    Outeiro, Tiago
    Zweckstetter, Markus
    Baehr, Mathias
    Toenges, Lars
    NEUROLOGY, 2016, 86
  • [46] Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
    AlDakheel, Amaal
    Kalia, Lorraine V.
    Lang, Anthony E.
    NEUROTHERAPEUTICS, 2014, 11 (01) : 6 - 23
  • [47] PARKINSON DISEASE Laying the foundations for disease-modifying therapies in PD
    Brundin, Patrik
    Wyse, Richard
    NATURE REVIEWS NEUROLOGY, 2015, 11 (10) : 553 - 554
  • [48] Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
    Amaal AlDakheel
    Lorraine V. Kalia
    Anthony E. Lang
    Neurotherapeutics, 2014, 11 : 6 - 23
  • [49] Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease A Review of Symptomatic and Potential Disease-Modifying Effects
    Schapira, Anthony H. V.
    CNS DRUGS, 2011, 25 (12) : 1061 - 1071
  • [50] Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease
    Evans, Jonathan R.
    Barker, Roger A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (08) : 1249 - 1258
12345